Industry Reports

AstraZeneca acquired Takedas respiratory business

AstraZeneca announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited . The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Neil Burrows
UK/Global
+44 20 7604 8032

Vanessa Rhodes
UK/Global
+44 20 7604 8037

Karen Birmingham
UK/Global
+44 20 7604 8120

Jacob Lund
Sweden
+46 8 553 260 20
Abigail Bozarth

US
+1 302 885 2677

Investor Enquiries

Thomas Kudsk Larsen
Oncology
+44 7818 524185

Eugenia Litz
RIA
+44 7884 735627

Nick Stone
CVMD
+44 7717 618834

Craig Marks
Finance
+44 7881 615764